An unusual form of cell death could lead to a Covid patient's lungs suffering extreme damage, potentially resulting in life-threatening conditions such as inflammation and acute respiratory disorders, according to new research.
The ability to inhibit this unusual form of cell death -- ferroptosis -- can offer doctors new ways of to treat Covid-19 lung disease, the study suggested.
Cell death, where a cell stops functioning, can be natural or could result from causes such as a disease or an injury.
The most common form of cell death involves cells "chopping up" the molecules inside, researchers explained, adding that this occurs in humans, both when they are ill or are ageing.
However, in ferroptosis, the relatively uncommon form of cell death, cells die because their outer fat layers collapse, the researchers at Columbia University, US, said.
In this study, they analysed human tissues and collected autopsies of patients who died of respiratory failure caused by Covid-19 infection. Samples from hamsters were also analysed.
The team found that most cells were dying through the ferroptosis mechanism, forming the underlying basis for lung disease in Covid patients.
Therefore, drugs that target and prevent the ferroptosis form of cell death could help improve the treatment course for Covid-19, the researchers said.
"This finding adds crucial insight to our understanding of how Covid-19 affects the body that will significantly improve our ability to fight life-threatening cases of the disease," said Brent Stockwell, chair of the department of biological sciences at Columbia, and co-lead author of the study published in the journal Nature Communications.
Previous studies have shown that ferroptosis, while instrumental to certain normal bodily processes, can also attack and kill healthy cells in patients with neurodegenerative diseases such as Parkinson's and Alzheimer's disease.
The authors said that the ability to inhibit ferroptosis could offer doctors new ways of combating cell death that should not be occurring, as in the case of Covid-19 lung disease.
"We're hopeful that these important new findings could improve our ability to confront this pernicious disease, which, in too many cases, still diminishes health outcomes and results in death," said Stockwell.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)